Navigation Links
Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference
Date:7/23/2014

SUNNYVALE, Calif., July 23, 2014 /PRNewswire/ -- Pelvalon, Inc. is making its clinical debut at the 2014 AUGS/IUGA Scientific Meeting in Washington, D.C. with the presentation of results from LIFE, a pivotal study of the Pelvalon's Vaginal Bowel Control (VBC) System.  Holly E. Richter, Ph.D, M.D., Director of the Division of Urogynecology and Pelvic Reconstructive Surgery at the University of Alabama at Birmingham and immediate Past President of the Society for Gynecological Surgeons (SGS), served as the National Principal Investigator and will be presenting the results at 11:55am on Thursday, July 24, 2014.

The LIFE study followed 61 women who used the VBC system.  At the 1-month primary endpoint, 79% of patients in the intent-to-treat cohort experienced treatment success (86% of patients in the per protocol cohort).  Risks were demonstrated to be very low, with zero device-related serious adverse events observed.  Additionally, 96% of the women who completed the trial found the insert to be comfortable, and 98% said they would recommend it to a friend.  "These results indicate that VBC may allow women to achieve a high degree of continence without risk of significant side effects and with an element of patient control," stated Dr. Richter. "This trial heralds a new era of treatment opportunity for women with bowel control problems."

Pelvalon's VBC System is the first to restore bowel control using a device placed in the vagina.  "Our goal is to provide a front-line therapy that poses minimal risk but delivers superior bowel control," said Pelvalon CEO Miles Rosen. "Today, women frequently don't report their symptoms.  We hope our technology will encourage patients and physicians to start a new dialogue about bowel control."

Over 20 million U.S. women suffer from loss of bowel control, also referred to as Fecal Incontinence (FI) or Accidental Bowel Leakage (ABL).  FI particularly affects women who have experienced pregnancy, childbirth, or nerve or muscle damage in the pelvic region.  Many women suffer in silence, fearing accidents and restricting their daily activities, because of the embarrassing stigma around the condition and the lack of successful, non-invasive treatments. 

About Vaginal Bowel Control
Restoring bowel control through the vagina is a new concept.  The VBC Insert is placed in the same location as a tampon.  The user inflates a balloon on the insert, which is designed to occlude the rectum to protect against unwanted stool passage.  Women can remove the insert at any time.  The VBC System is intended to offer women a non-invasive and non-surgical treatment option. 

The VBC System is limited by federal law to investigational use only and is not available for sale.

About Pelvalon
Headquartered in Sunnyvale, California, privately-held Pelvalon aims to change the lives of women who suffer from bowel control problems. Founded in 2010, Pelvalon's ground-breaking technology originated from Stanford University's Biodesign program, a collaboration between the schools of medicine and engineering.  Pevalon's investors include Norwich Ventures, a specialized venture capital firm focused on medtech.


'/>"/>
SOURCE Pelvalon
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , July 21, 2017 Did you know that PhRMA ... 2016? Or that combined spending on brand medicines, generics and the ... with brands accounting for just half of this (7 percent)? Or ... thirds of the world,s venture capital investments in high-growth biopharmaceutical startups? ... ...
(Date:7/19/2017)... , July 19, 2017  Mako Medical Laboratories partnered ... the Military Family Assistance Fund (MFA) to bring 140 ... to visit with their families one last time before ... coordinate the travel and logistics needed for these soldiers. ... soldiers and their families. We just wish we could ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based biotechnology company ... the completion of a $12.7 million Series A financing round. ... as the participation of existing investors. ... of New Ventures III and our current investors, and view ... of our platform technology to transform the course of PD ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... “Kids aren't born ... to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company ... which launches on Kickstarter on Monday, July 21st. , The kit uses colorful, ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... (ACL) offer patients improved quality of life five years after injury, according to ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five years ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia ... that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and ... and relapse. With such a challenging diagnosis that requires immediate action, patients ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... a telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... encrypted live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
(Date:7/20/2017)... ... , ... Girl Up Campaign Director, Melissa Kilby, released the ... of providing girls access to education in refugee settings. In May, Congressman Steve Chabot ... to Education in Vulnerable Settings Act.” Yesterday, companion legislation was introduced in the ...
Breaking Medicine News(10 mins):